1 Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273, (2020).
2 Burki, T. Understanding variants of SARS-CoV-2. Lancet 397, 462, (2021).
3 Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470-473, (2020).
4 Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682-687, (2020).
5 Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115-119, (2020).
6 Thomas, K. & Kolata, G. President Trump Received Experimental Antibody treatment, <https://www.nytimes.com/2020/10/02/health/trump-antibody-treatment.html> (2020).
7 Li, T., Zhang, T., Gu, Y., Li, S. & Xia, N. Current Progress and Challenges in the Design and Development of a Successful COVID-19 Vaccine. Fundamental Research 1, 139-150, (2021).
8 Wang, P. et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature, 1-9, (2021).
9 Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, (2021).
10 Wang, P. et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv, 2021.2003.2001.433466, (2021).
11 Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, (2021).
12 Saphire, E. O. et al. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. Science 293, 1155-1159, (2001).
13 Laursen, N. S. et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science 362, 598-602, (2018).
14 Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.e278, (2020).
15 Matheson, N. J. & Lehner, P. J. How does SARS-CoV-2 cause COVID-19? Science 369, 510-511, (2020).
16 Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263, (2020).
17 Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc National Acad Sci 117, 11727-11734, (2020).
18 Walls, A. C. et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell 176, 1026-1039.e1015, (2019).
19 Bruchez, A. et al. MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses. Science 370, 241, (2020).
20 Wells, A. I. & Coyne, C. B. Inhibiting Ebola virus and SARS-CoV-2 entry. Science 370, 167, (2020).
21 Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278, (2020).
22 Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119-1123, (2020).
23 Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630-633, (2020).
24 Huo, J. et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe 28, 445-454.e446, (2020).
25 Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290-295, (2020).
26 Chang, L. et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nat Commun 12, 1383, (2021).
27 Xiong, H.-L. et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infec 9, 2105-2113, (2020).
28 Tegally, H. et al. Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein. Nature, 1-8, (2021).
29 Li, Q. et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 182, 1284-1294.e1289, (2020).
30 Du, S. et al. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell 183, 1013-1023.e1013, (2020).
31 Clark, S. A. et al. Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. bioRxiv, 2020.2011.2013.381533, (2020).
32 Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950-957, (2020).
33 Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473-1479, (2020).
34 Barnes, C. O. et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell 182, 828-842.e816, (2020).
35 Hurlburt, N. K. et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv, 2020.2006.2012.148692, (2020).
36 Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010-1014, (2020).
37 Kreye, J. et al. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell 183, 1058-1069.e1019, (2020).
38 Piccoli, L. et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 183, 1024-1042.e1021, (2020).
39 Bertoglio, F. et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations. bioRxiv, 409318, (2020).
40 Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450-456, (2020).
41 Hanke, L. et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun 11, 4420, (2020).
42 Custódio, T. F. et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat Commun 11, 5588, (2020).
43 Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479-1484, (2020).
44 Wang, N. et al. Structure-based development of human antibody cocktails against SARS-CoV-2. Cell Res 31, 101-103, (2021).
45 Zhang, C. et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun 12, 264, (2021).
46 Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol 27, 846-854, (2020).
47 Jones, B. E. et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv, 2020.2009.2030.318972, (2020).
48 Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27, 950-958, (2020).
49 Wrapp, D. et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell 181, 1436-1441, (2020).
50 Lv, Z. et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369, 1505-1509, (2020).
51 Liu, H. et al. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity 53, 1272-1280.e1275, (2020).
52 Zheng, Q. et al. Viral neutralization by antibody-imposed physical disruption. Proceedings of the National Academy of Sciences of the United States of America 116, 26933-26940, (2019).
53 Bangaru, S. et al. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell 177, 1136-1152.e1118, (2019).
54 Watanabe, A. et al. Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism. Cell 177, 1124-1135.e1116, (2019).
55 Shen, C. et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine 9, eaam5752, (2017).
56 Vare?ková, E. et al. Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. 180, 107-116, (1995).
57 Yu, F. et al. Aquarium: an automatic data-processing and experiment information management system for biological macromolecular crystallography beamlines. Journal of Applied Crystallography 52, 472-477, (2019).
58 McCoy, A. J. et al. Phaser crystallographic software. Journal of Applied Crystallography 40, 658-674, (2007).
59 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta crystallographica. Section D, Biological crystallography 60, 2126-2132, (2004).
60 Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. Section D, Biological crystallography 66, 213-221, (2010).
61 Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Section D, Biological crystallography 66, 12-21, (2010).
62 Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature methods 14, 331, (2017).
63 Zhang, K. Gctf: Real-time CTF determination and correction. Journal of structural biology 193, 1-12, (2016).
64 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290-296, (2017).